Have a personal or library account? Click to login
Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells Cover

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells

Radiology and Oncology
Volume 52 (2018): Issue 4 (December 2018)
By: Tanja Mesti,  Nadia Bouchemal,  Claire Banissi,  Mohamed N. Triba,  Carole Marbeuf-Gueye,  Maja Cemazar,  Laurence Le Moyec,  Antoine F. Carpentier,  Philippe Savarin and  Janja Ocvirk  
Open Access
|Nov 2018

Figures & Tables

FIGURE 1

mIDH1-U87 vascular endothelial growth factor (VEGF) secretion and cell viability. (A) VEGF secretion ofmIDH1-U87 cells was assessed with immunoassay (B) Cell viability (%) of mIDH1-U87 cell lines after 72 h bevacizumab treatment at different cell line viability. Concentrations (0.1 mg/mL to 1 mg/mL) was assessed with the MTT assay. Bevacizumab has no significant effect (p > 0.05) on mIDH1-U87 cell line viability.
mIDH1-U87 vascular endothelial growth factor (VEGF) secretion and cell viability. (A) VEGF secretion ofmIDH1-U87 cells was assessed with immunoassay (B) Cell viability (%) of mIDH1-U87 cell lines after 72 h bevacizumab treatment at different cell line viability. Concentrations (0.1 mg/mL to 1 mg/mL) was assessed with the MTT assay. Bevacizumab has no significant effect (p > 0.05) on mIDH1-U87 cell line viability.

FIGURE 2

(A) Orthogonal projection to latent structure (OPLS)-DA score plot to discriminate metabolic effects of trehalose (blue) and bevacizumab (red) on mIDH1-U87 cells. (B) Projection of the spectra corresponding to the validation set. (C) OPLS loadings plot for mIDH1-U87 metabolic changes (significant changes marked with colours other than dark blue) after bevacizumab treatment. 1H CPMG spectrum of cells incubated with bevacizumab (D, RED).
(A) Orthogonal projection to latent structure (OPLS)-DA score plot to discriminate metabolic effects of trehalose (blue) and bevacizumab (red) on mIDH1-U87 cells. (B) Projection of the spectra corresponding to the validation set. (C) OPLS loadings plot for mIDH1-U87 metabolic changes (significant changes marked with colours other than dark blue) after bevacizumab treatment. 1H CPMG spectrum of cells incubated with bevacizumab (D, RED).

Principal discriminant metabolites_ An up arrow (↑) ↓↓ corresponds to an increase of the concentration induced by bevacizumab

Peak numberChemical shift (ppm)AttributionsConcentration variations Induced by Bev
1184/2.24/32OH-glutarate↑20%
23.22GPC/chol↑9%
32.11/2.34/2.55/3 02glutamate↑25%
41.475alanine↑25%
50.88(CH2)n-CH3↑32%
61.28(CH 2)n-CH2-(CH2)m↑20%
72.95creatine↑15%
83.02creatine↑25%
93.2Pcholine↑7%
103.3-3.42Taurine↑30%
113.6glycine↑ND
123.65-3.71GPC↑35%
DOI: https://doi.org/10.2478/raon-2018-0046 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 392 - 398
Submitted on: Nov 30, 2017
|
Accepted on: Oct 21, 2018
|
Published on: Nov 26, 2018
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
idh1 mutation,
malignant glioma,
bevacizumab,
metabolic,
fingerprint
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2018 Tanja Mesti, Nadia Bouchemal, Claire Banissi, Mohamed N. Triba, Carole Marbeuf-Gueye, Maja Cemazar, Laurence Le Moyec, Antoine F. Carpentier, Philippe Savarin, Janja Ocvirk, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 52 (2018): Issue 4 (December 2018)Next article